172 related articles for article (PubMed ID: 32360601)
1. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.
Avitan-Hersh E; Feng Y; Oknin Vaisman A; Abu Ahmad Y; Zohar Y; Zhang T; Lee JS; Lazar I; Sheikh Khalil S; Feiler Y; Kluger H; Kahana C; Brown K; Ruppin E; Ronai ZA; Orian A
J Invest Dermatol; 2020 Dec; 140(12):2466-2477. PubMed ID: 32360601
[TBL] [Abstract][Full Text] [Related]
2. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
3. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
4. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
5. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
[No Abstract] [Full Text] [Related]
6. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
[TBL] [Abstract][Full Text] [Related]
7. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Corre S; Tardif N; Mouchet N; Leclair HM; Boussemart L; Gautron A; Bachelot L; Perrot A; Soshilov A; Rogiers A; Rambow F; Dumontet E; Tarte K; Bessede A; Guillemin GJ; Marine JC; Denison MS; Gilot D; Galibert MD
Nat Commun; 2018 Nov; 9(1):4775. PubMed ID: 30429474
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
9. The rise of T-type channels in melanoma progression and chemotherapeutic resistance.
Alza L; Visa A; Herreros J; Cantí C
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188364. PubMed ID: 32275934
[TBL] [Abstract][Full Text] [Related]
10. RNF4-Dependent Oncogene Activation by Protein Stabilization.
Thomas JJ; Abed M; Heuberger J; Novak R; Zohar Y; Beltran Lopez AP; Trausch-Azar JS; Ilagan MXG; Benhamou D; Dittmar G; Kopan R; Birchmeier W; Schwartz AL; Orian A
Cell Rep; 2016 Sep; 16(12):3388-3400. PubMed ID: 27653698
[TBL] [Abstract][Full Text] [Related]
11. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
13. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.
Shen S; Faouzi S; Bastide A; Martineau S; Malka-Mahieu H; Fu Y; Sun X; Mateus C; Routier E; Roy S; Desaubry L; André F; Eggermont A; David A; Scoazec JY; Vagner S; Robert C
Nat Commun; 2019 Dec; 10(1):5713. PubMed ID: 31844050
[TBL] [Abstract][Full Text] [Related]
14. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
16. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
18. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
19. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
20. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
